Implementation of Empagliflozin in Patients With Diabetes Mellitus Type 2 and Established Cardiovascular Disease – Estimation of Five-Year Survival and Costs in Sweden
mediaposted on 2020-10-05, 11:49 authored by Lars Bernfort, Magnus Husberg, Ann-Britt Wiréhn, Ulf Rosenqvist, Staffan Gustavsson, Kristina Karlsdotter, Lars-Åke Levin
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.